论文部分内容阅读
目的比较格列美脲和瑞格列奈对早期糖尿病肾病的疗效。方法将80例2型糖尿病早期糖尿病肾病的患者随机分为格列美脲和瑞格列奈组。格列美脲组40例,口服格列美脲片,瑞格列奈组40例口服瑞格列奈片,疗程48周,观察两组治疗前后的血压(BP)、空腹血糖(FPG)、2小时血糖(2hPG)、稳态模型胰岛素抵抗指数(HOMA-IR)、糖化血红蛋白(HbA1c)、血清高敏C反应蛋白(Hs-CRP)、尿白蛋白排泄率(UAER)的变化。结果两组FPG、2hPG、HbA1c均有明显下降,但在降低BP、HOMA-IR、Hs-CRP、UAER方面格列美脲组优于瑞格列奈组。结论对于2型糖尿病早期糖尿病肾病的患者,格列美脲较瑞格列奈可更有效地降低UAER。
Objective To compare the effects of glimepiride and repaglinide on early diabetic nephropathy. Methods Eighty patients with type 2 diabetic patients with early diabetic nephropathy were randomly divided into glimepiride and repaglinide groups. 40 patients in glimepiride group, 40 patients in oral glimepiride tablets and repaglinide group were treated with repaglinide for 48 weeks. The levels of blood pressure (BP), fasting blood glucose (FPG) 2hPG, HOMA-IR, HbA1c, Hs-CRP and UAER were measured. Results The levels of FPG, 2hPG and HbA1c were significantly decreased in both groups, but glimepiride group was superior to repaglinide group in lowering BP, HOMA-IR, Hs-CRP and UAER. Conclusions Glimeporide is more effective in reducing UAER than repaglinide in type 2 diabetic patients with early diabetic nephropathy.